Laurus Labs has significantly boosted investor wealth, adding over Rs 40,000 crore in a year with a 120% stock rally. Driven by business im...

The Indian pharma sector made its initial global forays almost a quarter century ago. Companies sought out markets abroad, learnt to deal w...

Cohance Lifesciences shares surged over 43% in two days following the appointment of former Cipla CEO Umang Vohra as Executive Chairman and...

Shares of Cohance Lifesciences surged 20% on Monday after the appointment of former Cipla CEO Umang Vohra as its new Executive Chairman and...

The US has slapped up to 100% tariffs on patented drugs, sparing generics and biosimilars but exposing India’s speciality pharma players. S...

India's bulk-drug manufacturers are facing a severe cost crisis as prices of key solvents and intermediates have surged due to supply disru...

India is establishing itself in the global CDMO sector, driven by government incentives and low operational costs, making it an attractive ...

Suven Pharmaceuticals and Cohance Lifesciences plan to merge and aim to double their revenue to Rs 6,000 crore by FY29 through organic and ...

Lupin, a pharmaceutical company, has launched a new subsidiary named Lupin Manufacturing Solutions (LMS) to enter the Contract Development ...

Lupin Ltd appointed Abdelaziz Toumi as CEO of its new subsidiary, Lupin Manufacturing Solutions (LMS). Toumi, with over 20 years in biotech...

After the merger becomes effective, all shareholders of Cohance will be issued shares of Suven at the ratio of 11 shares of Suven for every...

Suven has been 50% owned by Advent since 2022 acquisition, with the remaining with public and institutional shareholders while Cohance is w...

Promoter of Suven Pharma, Advent International, had said last year that it would merge the two businesses post the buyout of its significan...

The US-based PE firm which is betting on India pharma, said that it intends to add more assets in the future with the vision to become one ...

The company had reported a net profit of Rs 202 crore during the same period of the previous year. On a quarter-on-quarter (QoQ) basis , th...

With a portfolio of 120 molecules, GLS is a leading developer of select high-value, non-commoditised APIs in chronic therapies. It earns on...

Piramal Pharma Solutions (PPS), the Contract Development and Manufacturing Organization (CDMO) of Piramal Pharma Limited, will acquire API ...